Refractory malignant pleural effusion
Conditions
Interventions
Case series:Elemene treatment
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years old; 2. patients with malignant tumor confirmed by pathology and / or cytology; 3. with or without histopathology and / or cytology to confirm that cancer cells were found in pleural effusion; 4. Complicated with moderate amount of pleural effusion (definition of moderate amount of pleural effusion: pleural effusion >=5 cm, with or without clinical symptoms such as chest tightness and shortness of breath in sitting position); 5. intracavitary administration of conventional chemotherapeutic drugs and / or biological response regulators was ineffective; 6. ECOG score =4x10^9/L, WBC >=1.5x10^9/L, platelet count >=80x10^9/L, hemoglobin >=80 g/L, and there was no tendency of bleeding; 9. Liver function examination: total bilirubin (TBIL) <=1.5 UNL, glutamic pyruvic transaminase (ALT), aspartate oxaloacetic transaminase (AST) <=2.5 UNL; 10. Renal function examination, serum creatinine <=1.5 times the normal upper limit; 11. Subjects of childbearing age must agree to take effective contraceptive measures during the trial, and lactating women must stop breastfeeding during the trial; 12. The patients volunteered to participate in this study and signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1. bleeding tendency, especially there has been obvious gastrointestinal bleeding in the past 4 weeks, or is receiving thrombolytic therapy; 2. Infectious pleural effusion; 3. accompanied by other malignant or uncontrollable diseases, defined as follows: Six months before entering the study, he suffered from myocardial infarction, unstable angina pectoris or congestive heart failure; With unstable arrhythmias that need clinical treatment; With infection that is difficult to control; "the deterioration of chronic obstructive pulmonary disease or the existence of other respiratory diseases requiring hospitalization; 4. patients who are receiving drug treatment or other clinical trials in other clinical studies; 5. those who are allergic to this product or its excipients; 6. pregnant women, suffering from mental or nervous system diseases, unable to cooperate; 7. reproductive female subjects and sexually active male subjects who are unwilling / unable to use medically acceptable forms of contraception; 8. the researchers think that any reason not suitable to be involved in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Countries
China
Contacts
Public ContactPing Li
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed